{
  "image_filename": "figure_p3_det_2_002.png",
  "image_path": "Zimmerman_et_al.__2023_/extracted/figures/figure_p3_det_2_002.png",
  "image_type": "Figure",
  "page_number": 3,
  "block_id": "det_2_002",
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "supports_claim": false,
  "explanation": "Flowchart diagram showing the numbers of participants included in primary analyses: recombinant quadrivalent influenza vaccine (RIV4) n=3,047, standard dose inactivated influenza vaccine (SD-IIV4) n=862, unvaccinated n=8,878, with subsets later shown (RIV4 n=291, SD-IIV4 n=114, unvaccinated n=1,398). does not support the claim because the figure only presents participant enrollment and grouping numbers without any immunogenicity or antibody response data comparing broadly cross-reactive antibodies or conserved HA regions between BEVS-derived and egg-derived vaccines.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Flowchart diagram showing the numbers of participants included in primary analyses: recombinant quadrivalent influenza vaccine (RIV4) n=3,047, standard dose inactivated influenza vaccine (SD-IIV4) n=862, unvaccinated n=8,878, with subsets later shown (RIV4 n=291, SD-IIV4 n=114, unvaccinated n=1,398).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the figure only presents participant enrollment and grouping numbers without any immunogenicity or antibody response data comparing broadly cross-reactive antibodies or conserved HA regions between BEVS-derived and egg-derived vaccines.",
    "confidence_notes": null
  }
}